ClinicalTrials.gg
CompletedNCT03107949RESCUE1Updated May 10, 2021

Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1)

An interventional study of Lungpacer DPTS (Diaphragm Pacing Therapy System) in Ventilator Induced Diaphragm Dysfunction, sponsored by Lungpacer Medical Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-10.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

An early feasibility study to investigate the safety and feasibility of the Lungpacer Diaphragm Pacing Therapy System (DPTS) as a therapy to recondition and strengthen the diaphragm of patients who have been intubated and invasively mechanically ventilated for > or = 7 days, have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during the latest SBT.

Read the detailed description

Mechanical ventilation (MV) is a life saving technology but can also cause damage to the lungs and diaphragm such as ventilator induced diaphragmatic dysfunction (VIDD). Research has shown that after being on mandatory MV and sedated the diaphragm begins to atrophy within as little as 18 hours. The DPTS is a temporary therapy that consists of the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) and the lungpacer Control Unit (LCU) system. The LIVE Catheter is a proprietary central venous catheter that incorporates pacing electrodes in strategic areas that align with the left and right phrenic nerves in order to stimulate the nerves to recruit the diaphragm. The LIVE Catheter can also be used for fluid delivery like any other central venous catheter. This early feasibility trial will investigate the safety and feasibility of the DPTS as a therapy to recondition and strengthen the diaphragm by stimulating the diaphragm through daily sessions so the patient may be more quickly liberated from MV. The patient population includes those who have been mechanically ventilated for > or = to 7 days, have failed two or more SBTs, and were not hypervolemic during the latest SBT. Patients must have resolution of the initial indication for placement on MV before entering the trial.

02

Conditions studied

  • Ventilator Induced Diaphragm Dysfunction

Keywords

  • Diaphragm atrophy
  • VIDD
  • weaning failure
  • SBT
03

In context

Lead sponsor

Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • have been mechanically ventilated for > or = 7 days and have not met criteria for successful weaning during this period; and
  • have failed at least two SBTs, one of which is the study specific SBT. (Self-extubation with subsequent reintubation within 48 hours is considered a failed SBT).

Exclusion criteria

Exclusion Criteria:

  • currently on extracorporeal membrane oxygenation (ECMO);
  • weaning failure due to hypervolemia;
  • known anatomy that prevents insertion of the LIVE Catheter into the left subclavian vein;
  • history of congenital heart disease;
  • clinically overt congestive heart failure;
  • pre-existing neuromuscular diseases that could affect the respiratory muscles;
  • pleural effusions occupying greater than one third of the pleural space on either side;
  • > or = 40;
  • known or suspected phrenic nerve paralysis;
  • any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
  • bacteremia (blood cultures must be negative for 48 hours);
  • current haemodynamic instability, shock or severe sepsis;
  • terminally ill with 6 months or less or not committed to full care;
  • known or suspected to be pregnant or lactating; and
  • actively participating in another clinical study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Lungpacer Diaphragm Pacing Therapy (DPTS)

    The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.

    Device: Lungpacer DPTS (Diaphragm Pacing Therapy System)

Interventions

  • DeviceLungpacer DPTS (Diaphragm Pacing Therapy System)

    Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.

    Also known as: LIVE Catheter; RESCUE 1

06

What researchers measure

Primary outcomes

  1. Successful Placement of the LIVE Catheter

    Successful placement of the LIVE Catheter via the Left Subclavian vein at the initiation of study will be assessed by placement confirmation via Chest Xray

    Time frame: You will undergo an evaluation immediately following the LIVE Catheter insertion procedure to confirm that the LIVE Catheter has been successfully placed in the correct position in your vein.

  2. Capture of phrenic nerve

    Successful capture and stimulation of at least one phrenic nerve as assessed by the change in the ventilator waveform and or diaphragm contraction.

    Time frame: Measured during daily Diaphragm Pacing Therapy sessions from time of LIVE Catheter insertion to time of extubation or day 30 whichever comes first

  3. Diaphragm contraction noted upon stimulation of the phrenic nerve

    Demonstration of the ability to contract the diaphragm via phrenic nerve stimulation will be evaluated by palpation of the diaphragm or visualization of the ventilator waveform change.

    Time frame: Measured during daily Diaphragm Pacing Therapy sessions from time of LIVE Catheter insertion to time of extubation or day 30 whichever comes first.

  4. Removal of LIVE Catheter

    Successful removal of the LIVE Catheter two days after date of extubation but before the end of the study on day 32

    Time frame: Removal of LIVE Catheter will occur 2 days after extubation or on day 30 if subject has not been extubated.

Other outcomes

  1. Evaluation of SAE's related to the use of the LIVE Catheter

    All SAE's related to the use of the LIVE Catheter will be evaluated to assess a reasonable safety profile associated with the LIVE Catheter insertion and removal procedure and the use of the DPTS in all study subjects.

    Time frame: From enrollment and insertion of the LIVE Catheter through LIVE Catheter removal or day 30 whichever comes first.

07

Study locations

4 sites
  • University of Florida Health Science Center - Shands
    Gainesville, Florida 32610, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study and it will be available through Syntactx.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Jan 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Apr 11, 2017
StartActual
Jun 20, 2017
Primary completionActual
Jan 30, 2018
CompletionActual
Feb 18, 2018
Last update
May 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03107949
Lead sponsor
Lungpacer Medical Inc.
Collaborators
Syntactx
Responsible party
Sponsor
First posted
Apr 11, 2017
Start date
Jun 20, 2017
Primary completion
Jan 30, 2018
Completion
Feb 18, 2018
Last update
May 10, 2021

Study contacts

Linda Clark, RN, BSN
study director · Vice Presdient of Clinical Affairs, Lungpacer Medical, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion